138 related articles for article (PubMed ID: 11213527)
1. Animal models of Huntington's disease: from basic research on neuronal death to assessment of new therapeutic strategies.
Brouillet E
Funct Neurol; 2000; 15(4):239-51. PubMed ID: 11213527
[No Abstract] [Full Text] [Related]
2. Neurodegeneration. Huntington's research points to possible new therapies.
Marx J
Science; 2005 Oct; 310(5745):43-5. PubMed ID: 16210515
[No Abstract] [Full Text] [Related]
3. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease.
Brustovetsky N; LaFrance R; Purl KJ; Brustovetsky T; Keene CD; Low WC; Dubinsky JM
J Neurochem; 2005 Jun; 93(6):1361-70. PubMed ID: 15935052
[TBL] [Abstract][Full Text] [Related]
4. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.
Laforet GA; Sapp E; Chase K; McIntyre C; Boyce FM; Campbell M; Cadigan BA; Warzecki L; Tagle DA; Reddy PH; Cepeda C; Calvert CR; Jokel ES; Klapstein GJ; Ariano MA; Levine MS; DiFiglia M; Aronin N
J Neurosci; 2001 Dec; 21(23):9112-23. PubMed ID: 11717344
[TBL] [Abstract][Full Text] [Related]
5. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
6. Huntington's disease.
Davies S; Ramsden DB
Mol Pathol; 2001 Dec; 54(6):409-13. PubMed ID: 11724916
[TBL] [Abstract][Full Text] [Related]
7. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
9. The use of transgenic and knock-in mice to study Huntington's disease.
Hickey MA; Chesselet MF
Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
[TBL] [Abstract][Full Text] [Related]
10. Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Hersch SM
Curr Opin Neurol; 2003 Aug; 16(4):501-6. PubMed ID: 12869810
[TBL] [Abstract][Full Text] [Related]
11. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
12. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
Menalled LB; Sison JD; Wu Y; Olivieri M; Li XJ; Li H; Zeitlin S; Chesselet MF
J Neurosci; 2002 Sep; 22(18):8266-76. PubMed ID: 12223581
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
14. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
[TBL] [Abstract][Full Text] [Related]
15. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
16. The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA; Mann DM
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
[TBL] [Abstract][Full Text] [Related]
17. Biomedicine. Huntingtin--profit and loss.
Trottier Y; Mandel JL
Science; 2001 Jul; 293(5529):445-6. PubMed ID: 11463904
[No Abstract] [Full Text] [Related]
18. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
19. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
20. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]